Spyre Historical Income Statement
| SYRE Stock | 27.27 0.38 1.37% |
Historical analysis of Spyre Therapeutics income statement accounts such as Total Operating Expenses of 255.3 M, Net Interest Income of 6.5 M, Interest Income of 6.5 M or Selling General Administrative of 29.8 M can show how well Spyre Therapeutics performed in making a profits. Evaluating Spyre Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Spyre Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Spyre Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Spyre Therapeutics is a good buy for the upcoming year.
Spyre |
About Spyre Income Statement Analysis
Spyre Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Spyre Therapeutics shareholders. The income statement also shows Spyre investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Spyre Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Spyre Therapeutics. It is also known as Spyre Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Spyre Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Spyre Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.At present, Spyre Therapeutics' Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 255.3 M, whereas Gross Profit is projected to grow to (74.1 K).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 111K | 837K | 6.1M | 6.5M | Net Interest Income | 111K | 837K | 6.1M | 6.5M |
Spyre Therapeutics income statement Correlations
Click cells to compare fundamentals
Spyre Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Spyre Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 901K | 1.6M | 2.0M | 2.0M | 744K | 1.1M | |
| Gross Profit | (901K) | (1.6M) | 16.7M | 365K | (78K) | (74.1K) | |
| Other Operating Expenses | 80.3M | 81.5M | 84.4M | 87.1M | 243.2M | 255.3M | |
| Operating Income | (80.3M) | (81.5M) | (65.6M) | (84.8M) | (242.3M) | (230.2M) | |
| Ebit | (80.3M) | (80.9M) | (65.7M) | (85.2M) | (243.0M) | (230.9M) | |
| Research Development | 64.6M | 59.6M | 57.1M | 58.6M | 89.5M | 56.0M | |
| Ebitda | (79.4M) | (79.3M) | (63.7M) | (83.2M) | (242.3M) | (230.2M) | |
| Total Operating Expenses | 79.4M | 81.5M | 84.4M | 87.1M | 243.2M | 255.3M | |
| Income Before Tax | (78.3M) | (80.9M) | (65.7M) | (84.0M) | (338.8M) | (321.9M) | |
| Total Other Income Expense Net | 2.1M | 588K | (11K) | 830K | (96.5M) | (91.7M) | |
| Net Income | (78.3M) | (80.9M) | (65.8M) | (83.8M) | (338.8M) | (321.9M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (37.90) | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.